Wegovy vs Ozempic: Cost, Results, and Which to Choose [2026]

Quick Answer: Wegovy and Ozempic contain the exact same active ingredient — semaglutide — but they're FDA-approved for different purposes and dosed differently. Wegovy (2.4 mg) is approved for chronic weight management and delivers 15–22% body weight loss in clinical trials. Ozempic (up to 2.0 mg) is approved for type 2 diabetes and typically produces 5–7% weight loss. Wegovy costs roughly $1,349/month at list price; Ozempic runs about $935/month. Both share similar side effects, though Wegovy's higher dose means more frequent GI symptoms during escalation. Your choice comes down to your primary diagnosis, insurance coverage, and weight loss goals.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications with serious potential side effects. Always consult a qualified healthcare provider before starting, stopping, or switching any medication. Individual results vary significantly based on health history, dosage, lifestyle, and genetics.

Affiliate Disclosure: Some links in this article may be affiliate links. We may earn a small commission if you purchase through these links, at no additional cost to you. This does not influence our editorial recommendations.

Wegovy vs Ozempic at a Glance: 2026 Comparison Table

Feature	Wegovy	Ozempic
Active Ingredient	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA Approval	Weight management (2021); cardiovascular risk reduction (2024)	Type 2 diabetes (2017); cardiovascular risk reduction
Maximum Dose	2.4 mg weekly injection	2.0 mg weekly injection
Average Weight Loss	15–22% of body weight	5–7% of body weight
List Price (Monthly)	~$1,349	~$935
Novo Nordisk Direct Price	$199/mo (first 2 months), then $349/mo through June 2026	Not currently offered
Administration	Weekly injection (pen); oral pill form approved 2025	Weekly injection (pen)
Dose Escalation Period	16–20 weeks	4–8 weeks
Oral Option Available	Yes (approved late 2025)	Rybelsus (oral semaglutide for diabetes)
Cardiovascular Benefit	FDA-approved for CV risk reduction in overweight/obese adults	FDA-approved for CV risk reduction in T2D
Common Side Effects	Nausea, diarrhea, vomiting, constipation, headache	Nausea, diarrhea, vomiting, constipation, headache

This table covers the basics, but the real differences — and the factors that should drive your decision — run much deeper. Let's break it down.

The Same Drug, Different Missions: What Sets Them Apart

Here's the part that confuses almost everyone: Wegovy and Ozempic are the same molecule. Semaglutide. Made by the same company. Injected the same way, on the same day of the week.

So why do two versions exist?

It comes down to FDA indication and dosing. The FDA approved Ozempic in 2017 specifically for type 2 diabetes management. It caps at 2.0 mg per week. Wegovy came later, in June 2021, approved for chronic weight management in adults with a BMI of 30 or higher — or 27 or higher with at least one weight-related comorbidity. Wegovy's maximum dose is 2.4 mg, roughly 20% more semaglutide per injection than Ozempic's ceiling.

That dose difference matters more than most people realize. Clinical trials consistently show that the weight loss response to semaglutide is dose-dependent. More drug, more weight loss. It's not a subtle difference — it's the gap between losing 15 pounds and losing 45.

Why the FDA Created Two Separate Approvals

The FDA treats obesity and diabetes as distinct conditions requiring separate clinical trial programs. Novo Nordisk ran the STEP trials (Semaglutide Treatment Effect in People with Obesity) for Wegovy and the SUSTAIN trials for Ozempic. Different patient populations. Different primary endpoints. Different dosing protocols.

This matters for your insurance coverage, which we'll dig into below. But the key takeaway: same drug, different labels, different doses, different price tags.

The Cardiovascular Angle

In March 2024, the FDA expanded Wegovy's label to include cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease. This was based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients taking semaglutide 2.4 mg compared to placebo.

Ozempic already had cardiovascular benefit data from the SUSTAIN-6 trial, but that was in people with type 2 diabetes — not the broader overweight/obese population. The SELECT trial was the first to prove heart benefits of a GLP-1 drug specifically for weight management, independent of diabetes status.

This distinction has changed the insurance conversation significantly in 2026. More on that shortly.

Cost Breakdown: What You'll Actually Pay in 2026

Let's talk money, because this is where most people's decision actually gets made — regardless of what the clinical data says.

List Prices

The manufacturer list prices (also called WAC — wholesale acquisition cost) as of early 2026:

Wegovy: approximately $1,349 per month (four single-use pen injectors)
Ozempic: approximately $935 per month (one multi-dose pen lasting four weeks)

These are the sticker prices. Almost nobody pays them. But they set the baseline for every negotiation between Novo Nordisk, pharmacy benefit managers (PBMs), and insurance companies.

Novo Nordisk's Direct Pricing Program

In a move that shook the market, Novo Nordisk launched a direct-to-consumer pricing option in late 2025. New self-pay patients (those paying out of pocket without insurance) can get Wegovy at:

$199/month for the first two months
$349/month thereafter
Available through June 30, 2026

This brought Wegovy's cash price below Ozempic's for the first time ever. If you're paying out of pocket, this makes the choice significantly easier — you get the higher dose (more weight loss) for less money.

For Ozempic, no equivalent direct pricing program exists as of April 2026. Cash-pay patients typically use manufacturer coupons or discount cards to bring costs down from the $935 list price. GoodRx and similar platforms show Ozempic prices ranging from $800 to $950 depending on pharmacy and location.

For a full breakdown of every savings option available, check our GLP-1 Cost Guide and Savings Programs.

Insurance Coverage: The Real Cost Decider

Insurance coverage varies wildly, and it's the single biggest factor in what you actually pay.

Commercial Insurance (Employer Plans):

About 50% of large employer plans now cover Wegovy for weight management, up from roughly 30% in 2024
Ozempic coverage for type 2 diabetes is nearly universal (~95% of plans)
Copays range from $25–$150/month for preferred formulary placement
Some plans require prior authorization, step therapy (trying lifestyle changes first), or documented BMI thresholds

Medicare:

As of 2026, Medicare Part D covers Wegovy for cardiovascular risk reduction following the SELECT trial data and the Inflation Reduction Act's expansion provisions
Ozempic coverage under Medicare Part D for diabetes has been standard
The out-of-pocket cap under Part D (now $2,000/year as of 2025) helps significantly
Check our GLP-1 Medicare Coverage Guide for specifics

Medicaid:

Coverage varies dramatically by state
Many state Medicaid programs still exclude weight loss medications
Ozempic for diabetes is generally covered

Self-Pay / Uninsured:

Novo Nordisk's direct pricing ($349/month ongoing for Wegovy) is the best option
Compounded semaglutide remains available but faces regulatory uncertainty — see our compounded semaglutide guide
Some telehealth platforms bundle medication + consultation for $300–$500/month

Cost Per Pound Lost: The Math Nobody Talks About

Here's a calculation worth doing. If Wegovy costs $349/month (Novo Nordisk direct price) and produces 15% body weight loss over 68 weeks for a 220-pound person:

Total cost over 68 weeks (~17 months): $5,933
Weight lost: 33 pounds
Cost per pound: ~$180

If Ozempic costs $900/month and produces 7% body weight loss over the same period for the same person:

Total cost over 17 months: $15,300
Weight lost: 15.4 pounds
Cost per pound: ~$994

Even adjusting for insurance copays, Wegovy at the direct price is dramatically more cost-effective per pound lost than Ozempic at retail. This math shifts if your insurance covers one but not the other, but it's worth calculating for your specific situation.

Weight Loss Results: Clinical Trial Data Head-to-Head

Now for the part most people actually care about. How much weight will you lose?

Wegovy: The STEP Trials

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program is one of the most comprehensive obesity treatment datasets ever collected. Key results:

STEP 1 (1,961 participants, non-diabetic, BMI ≥30 or ≥27 with comorbidity):

Average weight loss: 14.9% of body weight at 68 weeks
Placebo group lost 2.4%
86.4% of participants lost at least 5% of body weight
69.1% lost at least 10%
50.5% lost at least 15%

STEP 2 (1,210 participants, with type 2 diabetes):

Average weight loss: 9.6% of body weight at 68 weeks
Lower than STEP 1, confirming that diabetes blunts the weight loss response

STEP 3 (611 participants, with intensive behavioral therapy):

Average weight loss: 16.0% at 68 weeks
Demonstrates that combining medication with structured lifestyle intervention boosts results

STEP 5 (304 participants, 2-year data):

Average weight loss: 15.2% sustained at 104 weeks
Weight regain was minimal while on medication

The headline number: expect roughly 15–17% body weight loss on Wegovy with moderate lifestyle changes, or up to 20–22% with aggressive diet and exercise protocols, based on pooled trial data and real-world evidence through 2026.

Ozempic: The SUSTAIN Trials

Ozempic's clinical data comes primarily from the SUSTAIN trial program, which measured glycemic control as the primary endpoint. Weight loss was a secondary outcome:

SUSTAIN 1–5 (pooled analysis):

Average weight loss on Ozempic 1.0 mg: 4.5–6.5 kg (roughly 10–14 pounds) over 30–56 weeks
As a percentage of body weight: approximately 5–7%

SUSTAIN 7 (head-to-head vs Dulaglutide):

Ozempic 1.0 mg: 6.5 kg weight loss at 40 weeks
Significantly more than dulaglutide (Trulicity) at comparable doses

Ozempic 2.0 mg (higher dose, approved 2022):

SUSTAIN FORTE trial showed about 7–8% body weight loss
Closer to Wegovy's lower-dose results, but still well below the 2.4 mg level

Real-World Results vs Clinical Trials

Clinical trials have strict inclusion criteria, regular follow-ups, and motivated participants. Real-world data tells a different story — sometimes better, sometimes worse.

A 2025 retrospective analysis of over 35,000 semaglutide patients in U.S. electronic health records found:

Median weight loss at 12 months was 10.2% for patients on higher-dose semaglutide (Wegovy-equivalent dosing)
5.1% for standard-dose (Ozempic-equivalent dosing)
Roughly 25% of patients discontinued within the first 6 months, primarily due to side effects or cost
Patients who combined medication with structured diet programs lost 18–23% at 12 months

The gap between Wegovy and Ozempic holds up in the real world. It's smaller than the headline trial numbers suggest, but it's consistent and clinically meaningful.

How Wegovy and Ozempic Compare to Other GLP-1s

For context, here's where Wegovy and Ozempic sit relative to other options:

Zepbound (tirzepatide for weight loss): 20–26% weight loss in trials — the current leader
Wegovy (semaglutide 2.4 mg): 15–17% in real-world settings
Mounjaro (tirzepatide for diabetes): 15–21% depending on dose
Ozempic (semaglutide up to 2.0 mg): 5–7%
Saxenda (liraglutide 3.0 mg): 5–8%
Rybelsus (oral semaglutide 14 mg): 3–5%

If maximum weight loss is your goal and you have a choice, Zepbound and Wegovy are the top tier. For a detailed comparison of all options, see our Best GLP-1 for Weight Loss vs Diabetes guide.

Side Effects: What to Expect on Each Medication

Same molecule, same side effect profile — with one critical caveat. Dose matters. Higher doses mean more frequent and more intense side effects, at least initially.

Common Side Effects (Both Medications)

The GI side effects are the main event. In clinical trials, the following were reported at rates significantly above placebo:

Side Effect	Wegovy (2.4 mg)	Ozempic (1.0 mg)
Nausea	44%	20%
Diarrhea	30%	8.5%
Vomiting	24%	5%
Constipation	24%	3.1%
Abdominal pain	20%	5.7%
Headache	14%	13%
Fatigue	11%	4%
Injection site reactions	6%	0.2%

The nausea numbers tell the story. Nearly half of Wegovy users experience nausea at some point during treatment, compared to one in five on Ozempic. But context matters — most nausea occurs during dose escalation, peaks in the first 4–8 weeks of each new dose level, and resolves for the majority of patients.

The Dose Escalation Strategy

Both medications use a gradual dose escalation to minimize side effects:

Wegovy escalation (16–20 weeks):

Weeks 1–4: 0.25 mg
Weeks 5–8: 0.5 mg
Weeks 9–12: 1.0 mg
Weeks 13–16: 1.7 mg
Week 17+: 2.4 mg (maintenance)

Ozempic escalation (4–8 weeks):

Weeks 1–4: 0.25 mg
Weeks 5–8: 0.5 mg
Week 9+: 1.0 mg (can increase to 2.0 mg if needed)

Wegovy takes longer to reach its maintenance dose because it's going higher. This extended ramp-up is a feature, not a bug — it gives your body time to adapt. Patients who rush escalation or skip doses during the ramp tend to have worse GI symptoms.

Serious Side Effects and Warnings

Both medications carry the same black box warning for thyroid C-cell tumors (observed in rodent studies, unclear significance in humans). They share these serious but uncommon risks:

Pancreatitis: Reported in less than 1% of patients. Symptoms include severe abdominal pain radiating to the back. Stop the medication and seek immediate care.
Gallbladder problems: Approximately 2.6% of Wegovy patients in trials vs 1.2% on placebo. Rapid weight loss itself increases gallstone risk.
Acute kidney injury: Usually related to dehydration from vomiting or diarrhea. Staying hydrated is essential.
Diabetic retinopathy complications: Specifically for patients with type 2 diabetes and existing retinopathy. Rapid glucose improvement can temporarily worsen eye disease.
Hypoglycemia: Primarily a risk when combined with insulin or sulfonylureas. Rare as monotherapy.
Suicidal ideation: The FDA has investigated reports and as of 2026 has not found a causal link, but monitoring is recommended for patients with history of depression or mental health conditions.

Managing Side Effects: Practical Tips

Doctors and patients who've been through the adjustment period consistently recommend:

Eat smaller meals. Your stomach empties slower on semaglutide. Large meals are the fastest route to nausea.
Stay hydrated. Aim for 64+ ounces of water daily. Dehydration worsens every GI side effect.
Avoid high-fat meals during the first few weeks of each dose increase. Fat delays gastric emptying further.
Time your injection strategically. Many patients inject on Friday evening so any nausea peaks over the weekend.
Don't skip the escalation steps. The slow ramp exists for a reason.
Ginger or peppermint tea can help with mild nausea.
Talk to your doctor about anti-nausea medication (ondansetron) if symptoms are severe.

For a deeper dive into managing symptoms, check our GLP-1 Side Effects Complete Guide.

Who Should Choose Wegovy? Who Should Choose Ozempic?

This is the question everybody wants answered directly. Here's the framework.

Choose Wegovy If:

Your primary goal is weight loss and you have a BMI ≥30 (or ≥27 with a weight-related condition like hypertension, sleep apnea, or high cholesterol)
You don't have type 2 diabetes — Wegovy is specifically indicated for weight management
You want maximum semaglutide dosing — 2.4 mg vs Ozempic's 2.0 mg cap
Your insurance covers it or you qualify for Novo Nordisk's $349/month direct pricing
You have cardiovascular risk factors — Wegovy's SELECT trial data supports heart benefit in overweight/obese adults regardless of diabetes status
You prefer an oral option — the Wegovy pill form approved in 2025 eliminates injections entirely (see our Oral GLP-1 Pills Guide)

Choose Ozempic If:

You have type 2 diabetes and weight loss is a secondary (but welcome) benefit
Your insurance covers Ozempic but not Wegovy — this is still the most common scenario in 2026
You're sensitive to GI side effects — the lower maximum dose means milder symptoms for many patients
Your doctor recommends it for blood sugar control specifically
You're already on it and it's working — switching to Wegovy for "more weight loss" isn't always straightforward and requires a new prescription, prior authorization, and a dose adjustment period

The Off-Label Elephant in the Room

Let's address this directly: millions of Americans use Ozempic off-label for weight loss. They don't have type 2 diabetes. Their doctors prescribe Ozempic because their insurance won't cover Wegovy, and getting a diabetes medication approved is often easier than getting a weight loss medication approved.

Is this medically appropriate? In many cases, yes — the drug is identical. But there are practical downsides:

You're capped at 2.0 mg instead of 2.4 mg
If your insurance audits the claim and you don't have a diabetes diagnosis, coverage could be retroactively denied
It contributes to Ozempic shortages that affect actual diabetes patients
Your prescriber takes on liability for off-label use

The ethical and practical calculus is complicated. But the trend in 2026 is clearly toward broader Wegovy coverage, partly driven by the cardiovascular data and partly by employers realizing that covering weight management medication is cheaper than covering the downstream costs of obesity.

Special Situations

Switching from Ozempic to Wegovy: If you're on Ozempic 1.0 mg or 2.0 mg and switching to Wegovy, most doctors will start you at the Wegovy dose closest to your current Ozempic dose (1.0 mg or 1.7 mg) and escalate from there. You don't need to restart at 0.25 mg. See our switching guide for detailed protocols.

Considering Tirzepatide Instead: If neither Wegovy nor Ozempic feels right, Zepbound (tirzepatide) is worth discussing with your doctor. It's a dual GIP/GLP-1 receptor agonist that produces greater average weight loss than semaglutide in head-to-head trials. Mounjaro is the same molecule for diabetes. Our semaglutide vs tirzepatide comparison breaks down the differences.

Already Tried and Stopped Semaglutide: If you stopped Ozempic or Wegovy due to side effects, trying the other version at a lower dose with slower escalation may work. Some patients tolerate one formulation better than the other despite the identical active ingredient — differences in pen design, injection volume, and excipients may play a role.

The Oral Wegovy Option: A 2025–2026 Game Changer

One of the most significant developments is the FDA's approval of oral semaglutide for weight management. Previously, the only oral semaglutide was Rybelsus, which was approved for type 2 diabetes at a maximum dose of 14 mg daily.

The oral Wegovy formulation uses a higher dose (up to 50 mg daily) and has shown weight loss results approaching the injectable version — roughly 13–15% body weight loss in clinical trials. This is meaningful because:

No injections. A significant barrier for many patients is needle anxiety. About 20% of adults have some degree of needle phobia.
Daily dosing vs weekly. Some patients prefer the consistency of a daily routine over remembering a weekly injection.
Different side effect timing. The oral version may produce more consistent but milder GI effects compared to the weekly spike-and-trough pattern of injections.

The catch? Oral semaglutide must be taken on an empty stomach with a small amount of water, and you need to wait 30 minutes before eating or taking other medications. Compliance with these instructions directly affects absorption and efficacy.

For the full rundown on oral options, see our Oral GLP-1 Pills Guide.

Long-Term Considerations: What Happens When You Stop?

This is the question that doesn't get enough attention. Both Wegovy and Ozempic are intended as chronic (long-term, potentially lifelong) medications. What happens when you stop?

The Weight Regain Data

The STEP 1 extension trial showed that participants who stopped semaglutide 2.4 mg regained approximately two-thirds of their lost weight within one year of discontinuation. This isn't a failure of the medication — it's biology. Obesity is a chronic condition driven by neurohormonal mechanisms that don't reset after a course of treatment.

Specific numbers from the data:

Average weight loss on semaglutide at 68 weeks: 17.3%
Weight at 120 weeks (one year after stopping): participants had regained to approximately 5.6% below baseline
That means roughly 12 percentage points of weight loss were erased within a year

The Maintenance Dose Question

Some clinicians in 2026 are experimenting with lower maintenance doses — starting patients on Wegovy 2.4 mg, achieving target weight loss, then dropping to 1.0 mg or 1.7 mg for long-term maintenance. Early real-world data suggests this can preserve 70–80% of the weight loss while reducing cost and side effects. But this is not yet supported by randomized trial data.

Muscle Loss and the Protein Problem

One of the legitimate concerns with GLP-1 medications is muscle loss. In the STEP 1 trial, approximately 39% of the weight lost on semaglutide was lean mass (muscle and bone), compared to about 25% in typical caloric restriction. This is partly because the appetite suppression is so effective that protein intake drops significantly.

The countermeasure is straightforward but important:

Aim for 1.0–1.2 grams of protein per kilogram of ideal body weight daily
Resistance training 2–3 times per week is strongly recommended while on any GLP-1 medication
Monitor body composition, not just scale weight

For a complete guide on protecting muscle mass, see our article on preventing muscle loss on GLP-1 medications.

Insurance Trends and Policy Shifts in 2026

The insurance landscape for GLP-1 medications has shifted more in the past 18 months than in the previous five years combined. Several factors are driving this change, and they directly affect whether you'll pay $25 or $1,349 for your monthly semaglutide.

Employer Coverage Is Expanding Fast

Large employers are the bellwether. According to the Business Group on Health's 2026 survey, 52% of large employers now cover at least one anti-obesity medication, up from 41% in 2024 and just 26% in 2022. The primary driver isn't altruism — it's ROI. Companies are seeing reduced downstream healthcare spending (fewer joint replacements, fewer cardiovascular events, fewer diabetes diagnoses) in employee populations using GLP-1s. One widely cited analysis estimates that every dollar spent on GLP-1 coverage saves $2.40 in future medical claims over a five-year horizon.

The PBM Negotiation Game

Pharmacy benefit managers like Express Scripts, CVS Caremark, and Optum Rx wield enormous influence over which medications land on formularies. In 2026, the competitive pressure between Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro) has given PBMs significant leverage. Some PBMs are running exclusive deals — covering only one brand's weight loss drug while excluding the competitor — in exchange for deeper rebates. This means your access to Wegovy vs Zepbound may depend entirely on which PBM your employer uses, not on clinical evidence.

State-Level Mandates Emerging

At least six states introduced legislation in 2025–2026 requiring insurers to cover FDA-approved anti-obesity medications. Two have passed — New York and Colorado — with implementation timelines in late 2026 and early 2027 respectively. If you live in one of these states, your access picture may improve significantly within the next year.

How to Get Started: Practical Next Steps

Whether you're leaning toward Wegovy or Ozempic, the process looks similar:

Step 1: Determine Your Eligibility

For Wegovy:

BMI ≥30, OR
BMI ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)

For Ozempic:

Type 2 diabetes diagnosis (on-label)
Some doctors will prescribe off-label for weight management

Step 2: Check Your Insurance

Call the number on the back of your insurance card. Ask specifically:

"Is semaglutide (brand name Wegovy) covered for weight management?"
"Is semaglutide (brand name Ozempic) covered for type 2 diabetes?"
"What is my copay or coinsurance?"
"Is prior authorization required? If so, what criteria must be met?"

Step 3: Get a Prescription

Options include:

Your primary care doctor — most are now comfortable prescribing GLP-1s
Endocrinologist or obesity medicine specialist — if your PCP prefers a referral
Telehealth platforms — many now offer GLP-1 prescriptions with virtual consultations. See our best online GLP-1 programs guide

Step 4: Consider the Self-Pay Route

If insurance doesn't cover your preferred option:

Novo Nordisk's $349/month Wegovy program (through June 2026)
Manufacturer savings cards (check NovoCare.com)
Patient assistance programs for qualifying incomes
Our Savings Programs guide ranks every discount option

Step 5: Prepare for the First Weeks

Stock up on bland, easy-to-digest foods. Clear your schedule for the first injection day (many people feel fatigued or nauseous for 24–48 hours). Set up a protein tracking app. Tell your partner or housemates what to expect. And be patient — the first month is the hardest. It gets better.

Frequently Asked Questions

Can I switch from Ozempic to Wegovy mid-treatment?

Yes, and many patients do. Your doctor will typically match your current Ozempic dose to the equivalent Wegovy dose and continue escalation from there. You don't need to restart from scratch. However, you'll need a new prescription, and insurance prior authorization may be required for Wegovy.

Is Wegovy just a higher dose of Ozempic?

Essentially, yes. Both contain semaglutide. Wegovy goes up to 2.4 mg weekly while Ozempic caps at 2.0 mg. The medications are manufactured at different facilities with slightly different pen devices, but the active molecule is identical. The real difference is the FDA indication (weight loss vs diabetes) and the dosing range.

Why does my insurance cover Ozempic but not Wegovy?

Insurance companies categorize medications by therapeutic class. Diabetes medications have been covered for decades and are considered medically necessary. Anti-obesity medications have historically been excluded from many formularies because obesity was not treated as a disease the same way diabetes is. This is changing rapidly — the SELECT trial's cardiovascular data has given insurers a medical justification (and cost-effectiveness argument) to add Wegovy coverage. But the shift is uneven across plans and employers.

Can I use Ozempic for weight loss if I don't have diabetes?

Technically, your doctor can prescribe Ozempic off-label for weight loss. This is legal and common. However, you may face challenges with insurance coverage (since the prescription would be off-label), and you're limited to 2.0 mg maximum — below the 2.4 mg dose shown to produce optimal weight loss in clinical trials. If weight loss is your primary goal, Wegovy is the appropriate on-label choice.

What happens if I miss a dose of either medication?

If you miss your scheduled injection day, take it as soon as you remember — as long as it's within 5 days of the missed dose. If more than 5 days have passed, skip the missed dose and take the next one on your regular schedule. Do not double up. Missing occasional doses reduces efficacy but won't cause withdrawal symptoms. If you find yourself frequently missing doses, the oral Wegovy option may be worth discussing with your doctor.